Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Hodgkin Disease 3Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 32Etoposide 18romidepsin 17fludarabine 17Vincristine 17Doxorubicin 16Rituximab 14Prednisone 14Melphalan 14Gemcitabine 13Brentuximab Vedotin 13Lenalidomide 12Peripheral Blood Stem Cell Transplantation 11Cytarabine 11Whole-Body Irradiation 10Biopsy 1010-propargyl-10-deazaaminopterin 10pembrolizumab 9fludarabine phosphate 9Specimen Handling 9Busulfan 9Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Depsipeptides 8Carmustine 8Bortezomib 8duvelisib 7Vorinostat 7Methotrexate 7Magnetic Resonance Spectroscopy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × AFM13 × Clear all
NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

M.D. Anderson Cancer Center

Phase 1/2 Completed
45 enrolled
Lymphoid

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT03192202 2023-07-20

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Columbia University

Phase 1/2 Completed
18 enrolled 9 charts
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡